Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1431920
This article is part of the Research Topic Comprehensive Treatment Strategy for Improving Surgical Resection Rate of Retroperitoneal Sarcomas View all 7 articles

Intraoperative radiotherapy might not serve as a standard therapy for retroperitoneal liposarcoma： Insights from a Population-Based Propensity Score-Matched Study

Provisionally accepted
Xiao Zhou Xiao Zhou 1,2Zhuang Aobo Zhuang Aobo 1,2Xi Li Xi Li 3*Zhe Xi Zhe Xi 1,2*Yingxue Cheng Yingxue Cheng 1,2*Guangting Yan Guangting Yan 1,2*Wang Yue Wang Yue 1,2Gen Zhang Gen Zhang 1,2*Yangyang Huang Yangyang Huang 2Chenhe Zhang Chenhe Zhang 1,2*Fuan Xie Fuan Xie 1,2*Xin Ma Xin Ma 2*Ting Wu Ting Wu 1*Wengang Li Wengang Li 1,2*
  • 1 Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
  • 2 Department of Hepatobiliary Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
  • 3 Harvard University, School of Public Health, Boston, MA, 02115, US, Boston, United States

The final, formatted version of the article will be published soon.

    Difficulty in achieving complete resection leads to a poor prognosis for retroperitoneal soft tissue sarcoma, hence emphasizing the significance of adjuvant treatment. The benefit of preoperative radiotherapy for retroperitoneal liposarcoma was initially demonstrated by the STRASS trial. However, the impact of intraoperative radiotherapy (IORT) on retroperitoneal liposarcoma remains unexplored.Method Patients with retroperitoneal liposarcoma were identified in the Surveillance, Epidemiology, and End Results (SEER) database, treated between 2000 and 2019. Subsequently, a 1:1 propensity score-matched (PSM) analysis was conducted based on variables identified from a multivariate analysis. T-tests were used to assess differences in normally distributed continuous variables, while the rank-sum test was applied to variables that did not follow a normal distribution. The chi-squared test was utilized to evaluate differences in categorical variables. Ultimately, survival analysis was performed using SPSS to evaluate patient prognosis.Result A total of 2129 patients with retroperitoneal liposarcoma were included in our study. Age, sex, histology, grading, chemotherapy, and tumor size as independent prognostic risk factors for these patients through multivariate Cox regression analysis. Subsequently, 66 patients were included in the survival analysis through PSM, with 33 patients receiving IORT. Finally, the survival analysis revealed that there was no difference in overall survival among patients with retroperitoneal liposarcoma, regardless of whether they received IORT or not (p= 0.711).As a exploratory study, our findings suggest that patients may not derive benefit from intraoperative radiotherapy. These observations are intended to lay the groundwork for future prospective clinical studies.

    Keywords: Retroperitoneal liposarcoma, intraoperative radiotherapy, SEER, Propensity score matching, overall survival

    Received: 13 May 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Zhou, Aobo, Li, Xi, Cheng, Yan, Yue, Zhang, Huang, Zhang, Xie, Ma, Wu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xi Li, Harvard University, School of Public Health, Boston, MA, 02115, US, Boston, United States
    Zhe Xi, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Yingxue Cheng, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Guangting Yan, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Gen Zhang, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Chenhe Zhang, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Fuan Xie, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Xin Ma, Department of Hepatobiliary Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Ting Wu, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China
    Wengang Li, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China, Xiamen, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.